SCYNEXIS, Inc. has announced the resumption of patient dosing in the Phase 3 MARIO study of ibrexafungerp, an oral antifungal medication, following the lifting of a clinical hold by the FDA. This ...

Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and ...

SCYNEXIS (SCYX) to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the ...

SCYNEXIS, Inc. is progressing on its second-generation antifungal SCY-247, having initiated a Phase 1 trial in December 2024, with results expected in Q3 2025. The company also plans to present data ...

A new study published by JMIR Serious Games reports that popular video games, such as the Super Mario Bros. and Yoshi games, may offer meaningful emotional benefits for young adults. The research, ...

“We are pleased to announce the dosing of the first new patient in the Phase 3 MARIO study following the lifting of the clinical hold by the FDA in April,” said David Angulo, M.D., President and Chief ...